Form 4: BIODESIX CFO Sells Shares for Tax Obligations

BIODESIX CFO Robin Harper Cowie reported the acquisition of common stock from RSU vesting and subsequent sale of shares to cover tax liabilities.

Summary

• Robin Harper Cowie, CFO, Secretary, and Treasurer of BIODESIX INC (BDSX), reported transactions involving the company's common stock.
• On January 15, 2026, 805 shares of common stock were acquired through the vesting of Restricted Stock Units (RSUs).
• On January 16, 2026, 298 shares of common stock were sold at a weighted average price of $8.1493 per share.
• The sale of shares was conducted automatically to cover taxes upon the vesting of RSUs.
• Following these transactions, Robin Harper Cowie beneficially owns 13,654 shares of common stock directly.
• The reported numbers reflect a one-for-twenty reverse stock split effective September 15, 2025.
• The RSUs vest in four successive equal annual installments, measured from January 15, 2024, contingent on continued service.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the sale of shares reduces insider ownership, it is a routine, pre-planned transaction to cover tax liabilities associated with RSU vesting, which itself is a positive form of executive compensation.

Positives

• The vesting of 805 Restricted Stock Units (RSUs) indicates continued compensation and retention of a key executive.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-planned, non-discretionary sale.

Negatives

• A reduction of 298 shares in direct beneficial ownership by a key executive, even if for tax purposes.

Future Outlook

The remaining 1,609 Restricted Stock Units (RSUs) are expected to vest in future annual installments, generally subject to the Reporting Person's continued service with the Issuer.

Industry Context

This filing is a routine insider transaction report and does not provide specific insights into broader industry trends or competitive landscape. It reflects standard executive compensation practices involving equity awards.

Stakeholder Impact

• Shareholders: A minor reduction in direct insider ownership, but the transaction is routine and pre-planned, unlikely to signal any change in management's confidence.
• Employees (specifically the Reporting Person): Continued equity compensation through RSU vesting, reinforcing alignment with company performance.

Next Steps

• Future vesting of the remaining 1,609 Restricted Stock Units (RSUs) in successive equal annual installments from January 15, 2024.

Key Dates

Recommendation

This Form 4 details a routine, pre-planned insider transaction involving the vesting of Restricted Stock Units and the subsequent sale of shares to cover tax obligations. Such transactions are common for executives and do not typically reflect a change in the company's fundamental outlook or the executive's confidence. Therefore, it does not warrant a change in investment recommendation based solely on this filing.

Keywords

BIODESIX, BDSX, Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Share Sale, CFO, Executive Compensation, Tax Obligations